Logo

Bayer, NovaDx Enter $3M Gene Research Deal

Nov 21, 1998
Premium

VANCOUVER, BC--NovaDx International and its wholly-owned subsidiary Proteomix here entered into an agreement with German chemical and pharmaceutical company Bayer under which NovaDx will identify a series of osteoporosis genes. Bayer will pay up to $3 million to NovaDx based upon the successful completion of research milestones, and NovaDx will give Bayer access to a series of novel osteoclast-specific genes that may be potentially useful as drug targets for metabolic bone disease.

Filed under

Informatics
Breaking News
The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.